Revvity Inc

Revvity Inc(RVTY)股票分析

$152.640

-2.045 (-1.34%)收盤時

Loading chart…
最高
155.500
開盤
154.440
成交量加權均價
153.25
成交量
1.34M
市值
13.04B
最低
151.610
成交金額
204.79M
企業價值/稅息折舊攤銷前利潤(TTM)
20.86

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families.

AI 分析 of Revvity Inc (RVTY)

買進

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

估值指標

Revvity Inc(RVTY)目前預期本益比為 24.15,5 年平均預期本益比為 22.13。

預期本益比

合理
5 年均值 P/E
22.13
目前P/E
24.15
高估
25.11
低估
19.14

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
18.12
目前EV/EBITDA
20.86
高估
20.57
低估
15.67

預期股價營收比

高估
5 年均值 P/S
4.58
目前P/S
5.64
高估
5.29
低估
3.87

Alphio AI 對 RVTY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%RVTY

$80.72

情境價格

基

基準

基準 · 50%RVTY

$80.47

情境價格

悲

悲觀

悲觀 · 25%RVTY

$65.23

情境價格

持有 RVTY 的大戶

C

Campbell & Company, LP

+ 持有RVTY

+9.49%

3個月報酬率

E

EdgePoint Investment Group Inc.

+ 持有RVTY

+3.94%

3個月報酬率

M

Meridiem Capital Partners LP

+ 持有RVTY

+3.28%

3個月報酬率

V

Vaughan Nelson Investment Management, L.P.

+ 持有RVTY

+1.31%

3個月報酬率

P

Port Capital LLC

+ 持有RVTY

-1.25%

3個月報酬率

事件時間軸

2026-09-24 (ET)

10:00:00

Everpure Stock Rises $20.86 to $130.51

08:30:00

Revvity Launches GSP T1D 3plex Detection Kit

2026-09-15 (ET)

10:00:00

Skyworks and Others See Notable Stock Gains

2026-09-09 (ET)

06:30:00

Revvity Acquires French Biotech Company HCD

2026-08-04 (ET)

06:30:00

Company to Divest Immunodiagnostics Business in China

資訊

RVTY 常見問題 —— 由 Alphio AI 解答

Revvity, Inc. provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. It has specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Its segments include Life Sciences and Diagnostics. The Life Sciences segment provides products and services targeted towards life sciences customers. The segment offers instruments, reagents, software, subscriptions, detection and imaging technologies, and others. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the areas of reproductive health and emerging market diagnostics. The segment offers instruments, reagents, assay platforms and software to hospitals, medical labs, clinicians and medical research professionals to help improve the health of families. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Revvity Inc is a good buy right now due to its strong recent performance, with a current price of $154.18 and a year-to-date change of +57.09%. The stock is also showing positive momentum with an RSI of 61.707, indicating it is not overbought yet. Additionally, the forward P/E ratio of 24.15 suggests reasonable valuation compared to its growth prospects, especially with a gross margin of 57.13% in the latest quarter. However, the main risk is its high P/E ratio of 70.98, which indicates that the stock may be overvalued if growth does not meet expectations.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易